After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Organogenesis Holdings Inc is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Organogenesis Holdings Inc is $443.81M. A total of 0.55 million shares were traded on the day, compared to an average of 724.05K shares.
In the most recent transaction, Gillheeney Gary S. sold 55,615 shares of ORGO for 3.36 per share on Dec 13 ’24. After the transaction, the President and CEO now owns 3,044,779 company shares. In a previous transaction on Dec 16 ’24, Gillheeney Gary S. sold 5,585 shares at 3.49 per share. ORGO shares that President and CEO owns now total 3,039,194.
Among the insiders who sold shares, Gillheeney Gary S. disposed of 157,448 shares on Dec 11 ’24 at a per-share price of $3.64. This resulted in the President and CEO holding 3,143,753 shares of ORGO after the transaction. In another insider transaction, Gillheeney Gary S. sold 58,525 shares at $3.64 per share on Dec 10 ’24. Company shares held by the President and CEO now total 3,301,201.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ORGO has a high of $4.57 and a low of $2.16.
As of this writing, ORGO has an earnings estimate of $0.02 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.02 per share and a lower estimate of $0.02.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.10, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.50.
